Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its early and late-stage clinical studies, on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States. More than 180 abstracts have been accepted across 13 cancer types, including two “late breakers” and 15 oral presentations.
“New data to be presented from our industry-leading oncology portfolio, including our lung and haematology programmes, will demonstrate how our science-driven approach aims to improve outcomes for people living with cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “At ASCO, we look forward to sharing our progress and commitment to build the future of personalised healthcare in oncology.”
Further information on Roche’s contribution to the ASCO 2018 scientific programme, as well as Roche’s wider progress in cancer care, will be featured during the Roche Media Briefing from 09:00 - 10:45 CDT on Friday, 1 June at the Chicago Marriott Downtown Magnificent Mile, Chicago, IL, US. This event, independently organised by Roche, is open to journalists from outside the United States who have registered as media with the ASCO 2018 Annual Meeting. To register for the Roche Media Briefing, please follow this link: https://roche.cvent.com/d/6gq8k1/.
 More | 
